Altimmune, Inc. (ALT) Misses Q4 EPS by 10c

Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.54), $0.10 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $2.14 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS